24/7 Market News Snapshot 07 February, 2025 – Cyclo Therapeutics, Inc. Common Stock (NASDAQ:CYTH)

February 7, 2025

DENVER, Colo., 07 February, 2025 (247marketnews.com) – (NASDAQ:CYTH) are discussed in this article.
Cyclo Therapeutics, Inc. has recently garnered significant attention from investors, with its stock price experiencing a remarkable 50% surge in pre-market trading, rising to $1.155 from a previous close of $0.770. Trading volume has reached 5.99 million shares, reflecting robust investor enthusiasm and signaling strong market confidence in the company. This upward momentum could suggest promising developments for the biotechnology firm and has analysts keenly monitoring the situation for potential catalysts driving this increase.

In parallel, Cyclo Therapeutics is making strides in the clinical development of its innovative therapy, Trappsol® Cyclo™, for Niemann-Pick Disease Type C1 (NPC1). Recent presentations at the 21st Annual WORLDSymposium™ highlighted new data from the ongoing pivotal Phase 3 global study, TransportNPC™, which represents the most extensive controlled trial concerning investigational therapy for NPC1. The study, which completed its enrollment in May 2024, involves a diverse range of global clinical sites and aims to assess the therapy’s efficacy, including a sub-study focusing on patients aged newborn to three, allowing exploration of the therapy’s impact in earlier disease stages.

Dr. Ronen Spiegel, a prominent researcher involved in TransportNPC™, presented findings indicating that Trappsol® Cyclo™ promotes consistent lipid clearance in patients, with notable clinical improvements observed particularly in those with mild to moderate disease severity. Approximately 87.5% of treated patients demonstrated stability or enhancement in critical clinical measures within 24 to 48 weeks of treatment.

The emerging clinical data also showcase a favorable safety profile, consistent with earlier studies, where adverse effects were predominantly mild to moderate. As the study continues, Cyclo Therapeutics aims to gather additional information to better understand the broader implications of Trappsol® Cyclo™ and its potential impact on health outcomes for NPC patients. The company looks forward to an interim data readout in the first half of 2025, which may pave the way for regulatory submissions, reinforcing its commitment to addressing the substantial unmet medical needs of individuals living with NPC1.

Related news for (CYTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.